Orthocell Limited

OCC

AU000000OCC6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 01:52:20 2024-04-26 am EDT			5-day change	1st Jan Change
0.375 ^AUD	-1.32%		-5.06%	-8.54%

Apr. 15	Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	MT
Apr. 09	Orthocell Revenue Soars 19% to AU$1.61 Million in Q1	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Orthocell Limited

Orthocell Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 3%	Apr. 14	MT
Orthocell Revenue Soars 19% to AU$1.61 Million in Q1	Apr. 08	MT
Orthocell Completes First Stage of Remplir US Market Authorization Study	Mar. 24	MT
Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Orthocell Completes AU$3.5 Million Share Placement	Feb. 21	MT
Orthocell Submits Regulatory Application for Remplir in Singapore	Feb. 12	MT
Orthocell Limited Announces Resignation of Matthew Callahan from the Board	Jan. 15	CI
Orthocell Limited Appoints Kim Beazley AC as an Independent Non-Executive Director	Jan. 14	CI
Orthocell Completes Chair Transition Process	Dec. 21	MT
Orthocell Limited Announces Changes to its Board	Dec. 21	CI
Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023	23-10-24	CI
Orthocell Limited Announces Board Changes	23-10-24	CI
Orthocell Limited Announces Board Changes	23-09-21	CI
Orthocell Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Orthocell Secures Over AU$3 Million R&D Tax Rebate	23-06-20	MT
Orthocell Appoints Nonexecutive Chair	23-05-29	MT
Orthocell Limited Announces Board Changes	23-05-28	CI
Orthocell Begins Comparator Study for Product Marketing Initiatives	23-04-17	MT
Orthocell Limited Announces Appointments to its Medical and Scientific Advisory Board	23-03-28	CI
Orthocell Limited Appoints Ravi I. Thadhani as Independent Non-Executive Director	23-03-07	CI
Orthocell Announces Company Secretary Changes	23-02-28	CI
Orthocell Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Orthocell's Nerve Repair Product Joins Australian Prosthesis Reimbursement List	22-10-31	MT
Orthocell Says Cell Therapy Effective in Rotator Cuff Injuries	22-09-29	MT
Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients	22-09-28	CI

Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. It is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ORTHOCELL LIMITED	-8.54%	51.74M
VERTEX PHARMACEUTICALS INCORPORATED	-2.50%	103B
REGENERON PHARMACEUTICALS, INC.	+0.78%	95.71B
ARGENX SE	+1.28%	22.02B
BIONTECH SE	-17.23%	20.9B
GENMAB A/S	-9.05%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-14.73%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.89%	12.04B